Introduction
S-Kinase 0.75 Million is a medicine used to break down harmful blood clots that have formed in the blood vessels. It is used to treat patients who have suffered a recent heart attack. It is also used in treating conditions such as pulmonary embolism and stroke.
S-Kinase 0.75 Million is administered under the supervision of a doctor. Your doctor will decide the dose and duration of the medicine for you. The doctor may closely monitor your condition till you became stable.
Use of this medicine may cause injection site bleeding, allergic reaction, and decrease in blood pressure. It may increase your risk of bleeding also. Your doctor will explain the benefits and risks associated with this medicine before it is administered. You should continue all your other medicines that are advised by the doctor for your long-term treatment even after this injection.
This medicine is used with caution for some people. Thus, you must inform the doctor if you are suffering from any bleeding disorder, kidney or liver disease. Also, let your doctor know if you are pregnant or breastfeeding and about all the other medications that you are taking regularly.
Uses of S-Kinase 0.75 Million
- Heart attack
- Pulmonary embolism
Side effects of S-Kinase 0.75 Million
Common
- Allergic reaction
- Nausea
- Vomiting
- Injection site bleeding
How to use S-Kinase 0.75 Million
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How S-Kinase 0.75 Million works
S-Kinase 0.75 Million works by dissolving the harmful blood clots in the blood vessels. This restores the blood flow to the affected tissue, thereby preventing tissue death and improving outcomes.
What if you forget to take S-Kinase 0.75 Million?
If you miss a dose of S-Kinase 0.75 Million, please consult your doctor.
Indication
Acute Evolving Myocardial Infarction, Acute Massive Pulmonary Embolism, Deep Vein Thrombosis, Arterial Thrombosis or Embolism, Arteriovenous Cannulae Occlusion.
Adult Dose
Intravenous
Acute myocardial infarction
Adult: 1.5 million units as a single dose infused over 1 hr immediately after onset of symptoms.
Pulmonary thromboembolism ; Arteriovenous occlusions
Adult: Loading dose: 250,000 units infused over 30 min. Maintenance: 100,000 units/hr for 24-72 hr depending on the condition to be treated. For cerebral retinal thrombosis, 12 hr may be sufficient. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.
Child Dose
Intravenous
Pulmonary thromboembolism ; Arteriovenous occlusions
Child: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.
Contraindication
Severe hypertension, recent stroke, cerebral neoplasm, recent history of peptic ulcer disease, ulcerative colitis, pancreatitis, subacute bacterial endocarditis, coagulation defects also due to liver or kidney disease, recent surgery, childbirth. Hypersensitivity, increased risk of cerebral bleeding, trauma. Pregnancy. Active internal bleeding, bleeding GI lesions. Arteriovenous malformation or aneurysm; recent (within 10 days) facial or head trauma, intracranial or intraspinal surgery, More than 5 days and less than 12 months since previous Streptokinase therapy.
Mode of Action
Streptokinase forms a complex with plasminogen which then converts plasminogen to plasmin. Plasmin breaks down clots as well as fibrinogen and other plasma proteins.
Precaution
Mitral stenosis associated with AF. Streptokinase treatment within last 12 mth, use after prolonged or traumatic CPR; diabetic retinopathy. Elderly.
Side Effect
Fever, chills, back pain, abdominal pain, nausea, vomiting, arrhythmia, bruising, rash, pruritus, acute renal failure due to embolism and haemorrhage. Cerebral, peripheral and pulmonary embolism. Allergic reactions, liver enzyme abnormalities, hypotension.
Potentially Fatal: Haemorrhage; anaphylactic shock.
Interaction
Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid.
Potentially Fatal: Anticoagulants, heparin, antiplatelet agents e.g. aspirin and dipyridamole affect platelet function increasing the risk of haemorrhage.